ADIL
Adial Pharmaceuticals Inc (ADIL)
Healthcare • NASDAQ • $2.35-7.84%
- Symbol
- ADIL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.35
- Daily Change
- -7.84%
- Market Cap
- $5.69M
- Trailing P/E
- N/A
- Forward P/E
- -4.56
- 52W High
- $19.00
- 52W Low
- $1.31
- Analyst Target
- $7.00
- Dividend Yield
- N/A
- Beta
- 1.46
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Company websiteResearch ADIL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.